KR102006200B1 - 매크로라이드의 결정 형태들 및 그 용도들 - Google Patents

매크로라이드의 결정 형태들 및 그 용도들 Download PDF

Info

Publication number
KR102006200B1
KR102006200B1 KR1020127027222A KR20127027222A KR102006200B1 KR 102006200 B1 KR102006200 B1 KR 102006200B1 KR 1020127027222 A KR1020127027222 A KR 1020127027222A KR 20127027222 A KR20127027222 A KR 20127027222A KR 102006200 B1 KR102006200 B1 KR 102006200B1
Authority
KR
South Korea
Prior art keywords
rti
cem
peaks
delete delete
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127027222A
Other languages
English (en)
Korean (ko)
Other versions
KR20130056226A (ko
Inventor
데이비드 이. 페레이라
Original Assignee
셈프라 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102006200(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셈프라 파마슈티컬스, 인크. filed Critical 셈프라 파마슈티컬스, 인크.
Publication of KR20130056226A publication Critical patent/KR20130056226A/ko
Application granted granted Critical
Publication of KR102006200B1 publication Critical patent/KR102006200B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020127027222A 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들 Expired - Fee Related KR102006200B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187025895A Division KR20180101643A (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Publications (2)

Publication Number Publication Date
KR20130056226A KR20130056226A (ko) 2013-05-29
KR102006200B1 true KR102006200B1 (ko) 2019-08-01

Family

ID=44673574

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127027222A Expired - Fee Related KR102006200B1 (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들
KR1020187025895A Ceased KR20180101643A (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187025895A Ceased KR20180101643A (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP2550286B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR102006200B1 (enExample)
CN (2) CN108570083A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
MX361413B (es) * 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
KR101945324B1 (ko) 2010-05-20 2019-02-07 셈프라 파마슈티컬스, 인크. 매크로라이드들 및 케톨라이드들과 이의 중간체들을 제조하는 공정들
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
AU2014248014B2 (en) 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
AU2015301154A1 (en) * 2014-08-05 2017-02-23 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
EP3211997A4 (en) 2014-10-08 2018-10-24 President and Fellows of Harvard College 14-membered ketolides and methods of their preparation and use
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法
AU2020395150A1 (en) * 2019-12-02 2022-06-23 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055557A1 (en) * 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
BR9711661A (pt) 1996-09-04 1999-08-24 Abbott Lab Composto composi-Æo farmac-utica e processos para controlar uma infec-Æo bacteriana em um mam¡fero e para preparar um composto
PL337606A1 (en) 1997-06-11 2000-08-28 Pfizer Prod Inc Derivatives of erythromycin 9-oxime
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ES2273964T3 (es) 1998-12-10 2007-05-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
IL144178A0 (en) 1999-01-27 2002-05-23 Pfizer Prod Inc Ketolide antibiotics
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
NZ515027A (en) 1999-04-16 2004-01-30 Kosan Biosciences Inc Erythromycin derivatives as antibiotics
JP2002542197A (ja) 1999-04-16 2002-12-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ケトライド抗菌剤
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ES2270226T3 (es) 2000-03-15 2007-04-01 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de calidad no farmaceutica.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
DK1320355T3 (da) 2001-05-18 2006-07-31 Chiron Corp System til administration af en tobramycinformulering
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003072141A1 (en) 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
WO2004096823A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ATE373009T1 (de) 2004-04-28 2007-09-15 Alembic Ltd Verfahren zur vorbereitung von telithromycin
EP1794171A2 (en) 2004-07-28 2007-06-13 Ranbaxy Laboratories, Ltd. Ketolide derivatives as antibacterial agents
MX2007007598A (es) * 2004-12-21 2007-07-25 Pfizer Prod Inc Macrolidos.
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
EP2358379B1 (en) * 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
MX361413B (es) * 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055557A1 (en) * 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents

Also Published As

Publication number Publication date
RU2650883C2 (ru) 2018-04-18
MX361413B (es) 2018-12-05
US8759500B2 (en) 2014-06-24
CA2793884A1 (en) 2011-09-29
EP2550286B1 (en) 2015-12-09
KR20130056226A (ko) 2013-05-29
CN103080122A (zh) 2013-05-01
US20130252915A1 (en) 2013-09-26
HRP20160168T1 (hr) 2016-03-25
KR20180101643A (ko) 2018-09-12
EP3009442A1 (en) 2016-04-20
SI2550286T1 (sl) 2016-04-29
WO2011119604A1 (en) 2011-09-29
ES2564097T3 (es) 2016-03-17
DK2550286T3 (en) 2016-02-29
AU2016203986A1 (en) 2016-06-30
EP2550286A1 (en) 2013-01-30
AU2011232627A1 (en) 2012-10-18
MX2012010895A (es) 2013-02-15
HK1177937A1 (en) 2013-08-30
JP2020002168A (ja) 2020-01-09
JP2017081953A (ja) 2017-05-18
RU2012144614A (ru) 2014-04-27
US20160244472A1 (en) 2016-08-25
NZ602544A (en) 2014-11-28
MY162411A (en) 2017-06-15
US20130018008A1 (en) 2013-01-17
AU2016203986B2 (en) 2016-10-06
US8975386B2 (en) 2015-03-10
CN108570083A (zh) 2018-09-25
PL2550286T3 (pl) 2016-07-29
CA2793884C (en) 2019-09-10
BR112012023950A2 (pt) 2016-07-05
JP2013522367A (ja) 2013-06-13
IL222018B (en) 2019-05-30
AU2011232627B2 (en) 2016-03-17
JP2015063536A (ja) 2015-04-09
US20190040096A1 (en) 2019-02-07
JP5711352B2 (ja) 2015-04-30
JP6121387B2 (ja) 2017-04-26
EP2550286A4 (en) 2013-10-02
EP3009442B1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
KR102006200B1 (ko) 매크로라이드의 결정 형태들 및 그 용도들
AU2020262100B2 (en) A 7H-pyrrolo[2,3-d]pyrimidine JAK-inhibitor
MX2014005362A (es) Forma iv del clorhidrato de ivabradina.
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
SK283735B6 (sk) Forma VI 5,6-dichlór-2-(izopropylamino)-1-(beta-L-ribofuranozyl)- 1H-benzimidazolu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
CN118290384A (zh) 大豆苷元与哌嗪共晶物及制备方法和其组合物与用途
US20180370980A1 (en) Crystal form of substituted aminopyran derivative
HK1221229B (en) Crystalline forms of a macrolide, and uses therefor
HK1221229A1 (en) Crystalline forms of a macrolide, and uses therefor
HK1177937B (en) Crystalline forms of a macrolide, and uses therefor
CN107474057B (zh) (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
HK1182115A (en) Crystalline forms of a macrolide, and uses therefor
EP3004104A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2025032197A1 (en) Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
CZ20003709A3 (cs) Nové krystalické formy protivirivé benzimidazolové sloučeniny

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220727

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220727